Key facts
- This page summarizes Dov Bergwerk's Form 3 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
- 0 reported transactions and 7 derivative rows are listed below.
- Accepted by SEC: 08 Oct 2026, 16:01.
Dov Bergwerk - 29 Sep 2026 Form 3 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
- Reporting relationship
- Interim Cheif Legal Officer
- Issuer ticker
- TEVA
- Reported as of
- 29 Sep 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 08 Oct 2026, 16:01:09 UTC
- Prior SEC filing
- 01 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dov Bergwerk
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Dov Bergwerk filed Form 3 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 08 Oct 2026.
Change
- Previous filing in this sequence was filed on 01 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001997381
Primary reporting owner
Bergwerk Dov
- Relationship
- Interim Cheif Legal Officer
- Address
- C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HA'NEVIA STREET, TEL AVIV, ISRAEL
- Signature
- /s/ Dov Bergwerk
- Signature date
- 08 Oct 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TEVA
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 11,943
- Date
- 29 Sep 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TEVA
holding
Derivative
Stock Options (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Sep 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 17,505
- Exercise price
- $34.70
- Footnotes
- F1
TEVA
holding
Derivative
Stock Options (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Sep 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 8,755
- Exercise price
- $28.98
- Footnotes
- F2
TEVA
holding
Derivative
Restricted Share Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Sep 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 16,742
- Exercise price
- Footnotes
- F3, F4
TEVA
holding
Derivative
Restricted Share Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Sep 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 16,742
- Exercise price
- Footnotes
- F4, F5
TEVA
holding
Derivative
Restricted Share Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Sep 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 10,719
- Exercise price
- Footnotes
- F4, F6
TEVA
holding
Derivative
Restricted Share Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Sep 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 13,673
- Exercise price
- Footnotes
- F4, F7
TEVA
holding
Derivative
Restricted Share Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Sep 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 7,771
- Exercise price
- Footnotes
- F4, F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
Stock options were granted on March 3, 2017, with 4,376 having vested on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 4,377 having vested on March 3, 2021.
Footnote F2
Stock options were granted on May 24, 2017, with 2,188 having vested on each of May 24, 2018, May 24, 2019 and May 24, 2020 and 2,191 having vested on May 24, 2021.
Footnote F3
Restricted share units were granted on November 15, 2023, with 8,370 vested on each of November 15, 2024, November 15, 2025, 8,370 vesting on November 15, 2026, and 8,372 vesting on November 15, 2027.
Footnote F4
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
Footnote F5
Restricted share units were granted on March 4, 2024, with 8,370 vested on each of March 4, 2025 and March 4, 2026, 8,370 vesting on March 4, 2027, and 8,372 vesting on March 4, 2028.
Footnote F6
Restricted share units were granted on March 5, 2025, with 3,573 vested on March 5, 2026, and 3,573 vesting on each of March 5, 2027, March 5, 2028 and March 5, 2029.
Footnote F7
Restricted share units were granted on March 4, 2026, with 3,418 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 3,419 vesting on March 4, 2030.
Footnote F8
Restricted share units were granted on March 3, 2023, with 7,768 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026 and 7,771 vesting on March 3, 2027.